Qiang et al reported that the treatment of luseogliflozin reduced the liver weight with lipid accumulation and serum ALT levels in non-alcoholic steatohepatitis model mice [15]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.